@inproceedings{pagani-2021-ensidnet,
title = "{E}n{S}id{N}et: Enhanced Hybrid {S}iamese-Deep Network for grouping clinical trials into drug-development pathways",
author = "Pagani, Lucia",
editor = "Toutanova, Kristina and
Rumshisky, Anna and
Zettlemoyer, Luke and
Hakkani-Tur, Dilek and
Beltagy, Iz and
Bethard, Steven and
Cotterell, Ryan and
Chakraborty, Tanmoy and
Zhou, Yichao",
booktitle = "Proceedings of the 2021 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies",
month = jun,
year = "2021",
address = "Online",
publisher = "Association for Computational Linguistics",
url = "https://aclanthology.org/2021.naacl-main.24",
doi = "10.18653/v1/2021.naacl-main.24",
pages = "254--266",
abstract = "Siamese Neural Networks have been widely used to perform similarity classification in multi-class settings. Their architecture can be used to group the clinical trials belonging to the same drug-development pathway along the several clinical trial phases. Here we present an approach for the unmet need of drug-development pathway reconstruction, based on an Enhanced hybrid Siamese-Deep Neural Network (EnSidNet). The proposed model demonstrates significant improvement above baselines in a 1-shot evaluation setting and in a classical similarity setting. EnSidNet can be an essential tool in a semi-supervised learning environment: by selecting clinical trials highly likely to belong to the same drug-development pathway it is possible to speed up the labelling process of human experts, allowing the check of a consistent volume of data, further used in the model{'}s training dataset.",
}
<?xml version="1.0" encoding="UTF-8"?>
<modsCollection xmlns="http://www.loc.gov/mods/v3">
<mods ID="pagani-2021-ensidnet">
<titleInfo>
<title>EnSidNet: Enhanced Hybrid Siamese-Deep Network for grouping clinical trials into drug-development pathways</title>
</titleInfo>
<name type="personal">
<namePart type="given">Lucia</namePart>
<namePart type="family">Pagani</namePart>
<role>
<roleTerm authority="marcrelator" type="text">author</roleTerm>
</role>
</name>
<originInfo>
<dateIssued>2021-06</dateIssued>
</originInfo>
<typeOfResource>text</typeOfResource>
<relatedItem type="host">
<titleInfo>
<title>Proceedings of the 2021 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies</title>
</titleInfo>
<name type="personal">
<namePart type="given">Kristina</namePart>
<namePart type="family">Toutanova</namePart>
<role>
<roleTerm authority="marcrelator" type="text">editor</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Anna</namePart>
<namePart type="family">Rumshisky</namePart>
<role>
<roleTerm authority="marcrelator" type="text">editor</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Luke</namePart>
<namePart type="family">Zettlemoyer</namePart>
<role>
<roleTerm authority="marcrelator" type="text">editor</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Dilek</namePart>
<namePart type="family">Hakkani-Tur</namePart>
<role>
<roleTerm authority="marcrelator" type="text">editor</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Iz</namePart>
<namePart type="family">Beltagy</namePart>
<role>
<roleTerm authority="marcrelator" type="text">editor</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Steven</namePart>
<namePart type="family">Bethard</namePart>
<role>
<roleTerm authority="marcrelator" type="text">editor</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Ryan</namePart>
<namePart type="family">Cotterell</namePart>
<role>
<roleTerm authority="marcrelator" type="text">editor</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Tanmoy</namePart>
<namePart type="family">Chakraborty</namePart>
<role>
<roleTerm authority="marcrelator" type="text">editor</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Yichao</namePart>
<namePart type="family">Zhou</namePart>
<role>
<roleTerm authority="marcrelator" type="text">editor</roleTerm>
</role>
</name>
<originInfo>
<publisher>Association for Computational Linguistics</publisher>
<place>
<placeTerm type="text">Online</placeTerm>
</place>
</originInfo>
<genre authority="marcgt">conference publication</genre>
</relatedItem>
<abstract>Siamese Neural Networks have been widely used to perform similarity classification in multi-class settings. Their architecture can be used to group the clinical trials belonging to the same drug-development pathway along the several clinical trial phases. Here we present an approach for the unmet need of drug-development pathway reconstruction, based on an Enhanced hybrid Siamese-Deep Neural Network (EnSidNet). The proposed model demonstrates significant improvement above baselines in a 1-shot evaluation setting and in a classical similarity setting. EnSidNet can be an essential tool in a semi-supervised learning environment: by selecting clinical trials highly likely to belong to the same drug-development pathway it is possible to speed up the labelling process of human experts, allowing the check of a consistent volume of data, further used in the model’s training dataset.</abstract>
<identifier type="citekey">pagani-2021-ensidnet</identifier>
<identifier type="doi">10.18653/v1/2021.naacl-main.24</identifier>
<location>
<url>https://aclanthology.org/2021.naacl-main.24</url>
</location>
<part>
<date>2021-06</date>
<extent unit="page">
<start>254</start>
<end>266</end>
</extent>
</part>
</mods>
</modsCollection>
%0 Conference Proceedings
%T EnSidNet: Enhanced Hybrid Siamese-Deep Network for grouping clinical trials into drug-development pathways
%A Pagani, Lucia
%Y Toutanova, Kristina
%Y Rumshisky, Anna
%Y Zettlemoyer, Luke
%Y Hakkani-Tur, Dilek
%Y Beltagy, Iz
%Y Bethard, Steven
%Y Cotterell, Ryan
%Y Chakraborty, Tanmoy
%Y Zhou, Yichao
%S Proceedings of the 2021 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies
%D 2021
%8 June
%I Association for Computational Linguistics
%C Online
%F pagani-2021-ensidnet
%X Siamese Neural Networks have been widely used to perform similarity classification in multi-class settings. Their architecture can be used to group the clinical trials belonging to the same drug-development pathway along the several clinical trial phases. Here we present an approach for the unmet need of drug-development pathway reconstruction, based on an Enhanced hybrid Siamese-Deep Neural Network (EnSidNet). The proposed model demonstrates significant improvement above baselines in a 1-shot evaluation setting and in a classical similarity setting. EnSidNet can be an essential tool in a semi-supervised learning environment: by selecting clinical trials highly likely to belong to the same drug-development pathway it is possible to speed up the labelling process of human experts, allowing the check of a consistent volume of data, further used in the model’s training dataset.
%R 10.18653/v1/2021.naacl-main.24
%U https://aclanthology.org/2021.naacl-main.24
%U https://doi.org/10.18653/v1/2021.naacl-main.24
%P 254-266
Markdown (Informal)
[EnSidNet: Enhanced Hybrid Siamese-Deep Network for grouping clinical trials into drug-development pathways](https://aclanthology.org/2021.naacl-main.24) (Pagani, NAACL 2021)
ACL